1[1]Winton T, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage Ⅰ B and Ⅱ non-small cell lung cancer (NSCLC) Intergroup JBR. 10 [C]. Proc Am Soc Clin Oncol, 2004, 23 ( suppl ): 7018a.
2[2]Strauss G, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ⅰ B non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB)Protocol 9633 [C]. Proc Am Soc Clin Oncol, 2004, 23(suppl):7019a.
4[4]Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer:reappraisal with a rmeta-analysis of randomized controlled trials [J]. J Clin Oncol, 2004, 22(19):3860-3867.
5[5]Zojwalla NJ, Raftopoulos H, Gralla RJ. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients [C]. Proc Am Soc Clin Oncol, 2004, 23:7068a.
6[6]Onishi H, Nagata Y, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage Ⅰ non-small cell lung carcinoma:clinical outcomes in 273 cases of a Japanese multi-institutional study [C]. Proc Am Soc Clin Oncol, 2004, 23:7003a.
7[7]Vokes E, Herndon J, Kelly M, et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT)versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer(NSCLC) :Initial analysis of a randomized phase Ⅲ trial [C]. Proc Am Soc Clin Oncol, 2004, 23:7005a.
